Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:846:83-95.
doi: 10.1007/978-3-319-12114-7_4.

Regulation of blood vessels by prolactin and vasoinhibins

Carmen Clapp  1 , Stéphanie Thebault, Yazmín Macotela, Bibiana Moreno-Carranza, Jakob Triebel, Gonzalo Martínez de la Escalera
Affiliations
Review

Regulation of blood vessels by prolactin and vasoinhibins

Carmen Clapp et al. Adv Exp Med Biol. 2015.

Erratum in

  • Erratum.
    Diakonova M. Diakonova M. Adv Exp Med Biol. 2015;846:E1-2. doi: 10.1007/978-3-319-12114-7_13. Adv Exp Med Biol. 2015. PMID: 25804496 No abstract available.

Abstract

Prolactin (PRL) stimulates the growth of new blood vessels (angiogenesis) either directly through actions on endothelial cells or indirectly by upregulating proangiogenic factors like vascular endothelial growth factor (VEGF). Moreover, PRL acquires antiangiogenic properties after undergoing proteolytic cleavage to vasoinhibins, a family of PRL fragments (including 16 kDa PRL) with potent antiangiogenic, vasoconstrictive, and antivasopermeability effects. In view of the opposing actions of PRL and vasoinhibins, the regulation of the proteases responsible for specific PRL cleavage represents an efficient mechanism for controlling blood vessel growth and function. This review briefly describes the vascular actions of PRL and vasoinhibins, and addresses how their interplay could help drive biological effects of PRL in the context of health and disease.

PubMed Disclaimer

Publication types

LinkOut - more resources